UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of Benefits on Myocardial Performance of Cellular Cardiomyoplasty with Skeletal Myoblasts and Fibroblasts

Cell transplantation, 2000-05, Vol.9 (3), p.359-368

2000

Volltextzugriff (PDF)

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium

The Journal of heart and lung transplantation, 1999-12, Vol.18 (12), p.1173-1180

1999

Volltextzugriff (PDF)

Cellular Cardiomyoplasty Improves Diastolic Properties of Injured Heart

The Journal of surgical research, 1999-08, Vol.85 (2), p.234-242

1999

Volltextzugriff (PDF)

Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine

Annals of surgical oncology, 2004-02, Vol.11 (S2), p.S69-S70

2004

Volltextzugriff (PDF)

Using Weighted Differences in Hazards as Effect Sizes for Survival Data

Journal of statistical theory and practice, 2022-03, Vol.16 (1), Article 12

2022

Volltextzugriff (PDF)

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer

International journal of oncology, 2004-12, Vol.25 (6), p.1769

2004

Volltextzugriff (PDF)

Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7536-7545

2005

Volltextzugriff (PDF)

Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds

Surgery, 2017-04, Vol.161 (4), p.1164-1173

2017

Volltextzugriff (PDF)

Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3067-3067

2008

Volltextzugriff (PDF)

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3016-3016

2008

Volltextzugriff (PDF)

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

Clinical cancer research, 2005-10, Vol.11 (20), p.7470-7479

2005

Volltextzugriff (PDF)

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients

Clinical cancer research, 2006-01, Vol.12 (2), p.478-486

2006

Volltextzugriff (PDF)

Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-06-09

2013

Volltextzugriff (PDF)

Prognostic significance of HLA-A2 status in breast cancer patients

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.9702-9702

2005

Volltextzugriff (PDF)

Management of gastrointestinal stromal tumors

The Surgical clinics of North America, 2008-06, Vol.88 (3), p.599-614

2008

Volltextzugriff (PDF)

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial

Journal of the American College of Surgeons, 2010-02, Vol.210 (2), p.140-147

2010

Volltextzugriff (PDF)

Management of retroperitoneal sarcomas

The Surgical clinics of North America, 2008-06, Vol.88 (3), p.583-597

2008

Volltextzugriff (PDF)

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2575-2575

2005

Volltextzugriff (PDF)

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex registered technology

Oncology reports, 2007-03, Vol.17 (3), p.687-694

2007

Volltextzugriff (PDF)

Management of extremity soft tissue sarcomas

The Surgical clinics of North America, 2008-06, Vol.88 (3), p.539-557

2008

Volltextzugriff (PDF)

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients

Journal of the American College of Surgeons, 2009-02, Vol.208 (2), p.193-201

2009

Volltextzugriff (PDF)

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37)

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.3134

2009

Volltextzugriff (PDF)

Evolving Treatment Strategies for Gallbladder Cancer

Annals of surgical oncology, 2009-08, Vol.16 (8), p.2101-2115

2009

Volltextzugriff (PDF)

Evolving Treatment Strategies for Gallbladder Cancer

Annals of surgical oncology, 2009-08, Vol.16 (8), p.2101-2115

2009

Volltextzugriff (PDF)

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Clinical cancer research, 2008-02, Vol.14 (3), p.797-803

2008

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Englisch
(46)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of Benefits on Myocardial Performance of Cellular Cardiomyoplasty with Skeletal Myoblasts and Fibroblasts

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium

Cellular Cardiomyoplasty Improves Diastolic Properties of Injured Heart

Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine

Using Weighted Differences in Hazards as Effect Sizes for Survival Data

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer

Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients

Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds

Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients

Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions

Prognostic significance of HLA-A2 status in breast cancer patients

Management of gastrointestinal stromal tumors

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial

Management of retroperitoneal sarcomas

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex registered technology

Management of extremity soft tissue sarcomas

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37)

Evolving Treatment Strategies for Gallbladder Cancer

Evolving Treatment Strategies for Gallbladder Cancer

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Suchergebnisse filtern